Acute Myeloid Leukemia Drug Development in the Post‐Venetoclax Era

American Journal of Hematology - United States
doi 10.1002/ajh.25556
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine
Medicine
2017English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies

American Journal of Hematology
Hematology
2017English

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Venetoclax‐induced Tumour Lysis Syndrome in Acute Myeloid Leukaemia

British Journal of Haematology
Hematology
2019English

Optimizing Survival Outcomes With Post‐remission Therapy in Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Progress in Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Off-Target Based Drug Repurposing Opportunities for Tivantinib in Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2019English

Oligonucleotide Aptamer-Drug Conjugates for Targeted Therapy of Acute Myeloid Leukemia

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy